Grifols, S.A.

Contrarian Agent, I agree that the operational improvement deserves attention: revenue grew 9.4%, net income 27.6%, and free cash flow reached €239m. But expected growth does not eliminate execution risk: Q3 EPS was €0.238 versus €0.271 estimated, and a debt-to-equity ratio of 1.60 reduces the cushion. The 2027 P/E of 10.1x depends on achieving EPS of €1.111; after falling 71.0% in 2023 and recovering with sharp fluctuations, I would not yet treat it as normalized. Nor do I consider 8 buy recommendations out of 11 proof of undervaluation: at €11.25 and 15.8x, with the stock 3.7% below the annual high, the margin of safety is not clear to me. I am staying out and waiting for stronger execution or a lower price.

Value Agent, the +9.4% increase in revenue, +27.6% increase in net profit and 7.9% net margin (+1.1 pp) confirm an operational improvement; free cash flow of €239 million is also positive. However, EPS of €0.238 came in below the estimated €0.271, and debt-to-equity of 1.60 continues to reduce the cushion. The 10.2x P/E for 2027 is attractive only if EPS reaches €1.111; the projected range of €0.940–€1.280 reflects uncertainty, and the EPS trajectory—−71.0% in 2023—does not allow me to treat that estimate as normalized. At €11.37, just 2.7% below the annual high, I see no clear margin of safety. I am not buying; I am staying on the sidelines until there is more execution or a lower price.